Jack Mannheimer
Psychiatry · West Mifflin, PANPI 1619076353
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 622 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2021 at $2,338 and has fallen 98.7% since, to $29 in 2024. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$849
- Lundbeck LLC$678
- Sunovion Pharmaceuticals Inc.$614
- Neurocrine Biosciences, Inc.$608
- Takeda Pharmaceuticals U.S.A., Inc.$530
- plus $3K from 16 others
What the payments were for
- Food & beverage$9,10697%
- Education$2473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 241 | $3,280 |
| Teva Pharmaceuticals USA, Inc. | 39 | $849 |
| Lundbeck LLC | 57 | $678 |
| Sunovion Pharmaceuticals Inc. | 53 | $614 |
| Neurocrine Biosciences, Inc. | 33 | $608 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $530 |
| Alkermes, Inc. | 27 | $468 |
| Otsuka America Pharmaceutical, Inc. | 23 | $414 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $400 |
| Almatica Pharma LLC | 23 | $360 |
| Vanda Pharmaceuticals Inc. | 15 | $296 |
| Eisai Inc. | 16 | $242 |
| Jazz Pharmaceuticals Inc. | 13 | $196 |
| Indivior Inc. | 5 | $111 |
| Johnson & Johnson | 5 | $80 |
| Bausch Health US, LLC | 4 | $54 |
| Corium, LLC | 5 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $46 |
| Shire North American Group Inc | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $18 |
How this compares
$9,353 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 34 | $47,934 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,889 |
| Bupropion XlBupropion Hcl | 127 | $3,930 |
| Aripiprazole | 72 | $2,955 |
| Trazodone Hcl | 255 | $2,464 |
| Alprazolam | 311 | $1,819 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 80 | $1,801 |
| Quetiapine Fumarate | 108 | $1,774 |
| Clonazepam | 223 | $1,594 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $1,401 |
| Vilazodone Hcl | 15 | $1,195 |
| Bupropion Hcl SrBupropion Hcl | 61 | $1,126 |
| Gabapentin | 69 | $1,119 |
| Lorazepam | 138 | $1,097 |
| Duloxetine Hcl | 55 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $3,280 | $47,93434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $530 | $5,88911 claims |
| Almatica Pharma LLCSertraline Hcl | $360 | $99464 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in West Mifflin
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.